{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:30:00Z","timestamp":1761895800872,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.4158\/ep13411.or","type":"journal-article","created":{"date-parts":[[2014,2,11]],"date-time":"2014-02-11T21:09:27Z","timestamp":1392152967000},"page":"785-791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and Safety of Insulin Degludec 200 U\/mL and Insulin Degludec 100 U\/mL in Patients with Type 2 Diabetes (Begin: Compare)"],"prefix":"10.1016","volume":"20","author":[{"given":"Bruce","family":"Bode","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Chaykin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Niemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasmus","family":"Rab\u00f8l","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Rodbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP13411.OR_bb0010","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2146\/ajhp090554","article-title":"Use of concentrated insulin human regular (U-500) for patients with diabetes.","volume":"67","author":"Segal","year":"2010","journal-title":"Am J Health Syst Pharm."},{"key":"10.4158\/EP13411.OR_bb0020","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/pgmj.2008.073379","article-title":"Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus","volume":"85","author":"Crasto","year":"2009","journal-title":"Postgrad Med J"},{"key":"10.4158\/EP13411.OR_bb0025","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40261-013-0096-7","article-title":"A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U\/mL formulations of ultra-long-acting insulin degludec","volume":"33","author":"Korsatko","year":"2013","journal-title":"Clin Drug Investig."},{"key":"10.4158\/EP13411.OR_bb0030","first-page":"1489","volume":"379","author":"Heller","year":"2012"},{"key":"10.4158\/EP13411.OR_bb0035","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(12)60205-0","article-title":"Insulin degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial","volume":"379","author":"Garber","year":"2012","journal-title":"Lancet"},{"key":"10.4158\/EP13411.OR_bb0040","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.2337\/dc12-1205","article-title":"Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)","volume":"35","author":"Zinman","year":"2012","journal-title":"Diabetes Care"},{"key":"10.4158\/EP13411.OR_bb0045","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/dom.12032","article-title":"Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.","volume":"15","author":"Ratner","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/EP13411.OR_bb0050","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.2337\/dc12-2329","volume":"36","author":"Gough","year":"2013","journal-title":"Diabetes Care"},{"key":"10.4158\/EP13411.OR_bb0055","first-page":"403","article-title":"Declaration of Helsinki Ethical principles for medical research involving human subjects","volume":"107","year":"2009","journal-title":"J Indian Med Assoc."},{"key":"10.4158\/EP13411.OR_bb0060","first-page":"199","article-title":"ICH Harmonised Tripartite guideline:Guideline for Good Clinical Practice.","volume":"47","year":"2001","journal-title":"J Postgrad Med."},{"key":"10.4158\/EP13411.OR_bb0065","first-page":"1294","article-title":"The pharmacokinetic and pharmacodynamic properties of regular U-500 insulin in healthy subjects","volume":"56","author":"Khan","year":"2007","journal-title":"Diabetes"},{"key":"10.4158\/EP13411.OR_bb0070","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","article-title":"Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study","volume":"29","author":"Peyrot","year":"2012","journal-title":"Diabet Med"},{"key":"10.4158\/EP13411.OR_bb0075","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.4158\/EP13411.OR_bb0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1185\/03007995.2011.644427","article-title":"Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning.","volume":"28","author":"Nadeau","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.4158\/EP13411.OR_bb0085","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1517\/17425247.2012.721774","article-title":"Healthcare professional and patient perceptions of a new prefilled insulin pen versus vial and syringe.","volume":"9","author":"Lajara","year":"2012","journal-title":"Expert Opin Drug Deliv"},{"key":"10.4158\/EP13411.OR_bb0090","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.4158\/EP13411.OR_bb0095","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1463-1326.2009.01060.x","article-title":"Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.","volume":"11","author":"Blonde","year":"2009","journal-title":"Diabetes Obes Metab."},{"key":"10.4158\/EP13411.OR_bb0100","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/dom.12032","article-title":"Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.","volume":"15","author":"Ratner","year":"2013","journal-title":"Diabetes Obes Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20412479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20412479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/T515526377267370.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:58:02Z","timestamp":1761515882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20412479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1530891X20412479"],"URL":"https:\/\/doi.org\/10.4158\/ep13411.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Insulin Degludec 200 U\/mL and Insulin Degludec 100 U\/mL in Patients with Type 2 Diabetes (Begin: Compare)","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP13411.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}